234 related articles for article (PubMed ID: 30125265)
1. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Mu Y; Sun D
Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
[TBL] [Abstract][Full Text] [Related]
2. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
[TBL] [Abstract][Full Text] [Related]
4. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Sambade MJ; Kimple RJ; Camp JT; Peters E; Livasy CA; Sartor CI; Shields JM
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):575-81. PubMed ID: 20457354
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
14. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
15. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
17. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
19. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]